1. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series 
Attaphol Pawarode, Shin Mineishi, Pavan Reddy, Thomas M. Braun, Yasser A. Khaled, Sung W. Choi, John M. Magenau, Andrew C. Harris, James A. Connelly, Carrie L. Kitko, Brian L. Parkin, Steven C. Goldstein, Gregory A. Yanik, John E. Levine, James L. Ferrara, Daniel R. Couriel 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 1, Pages (January 2016)
DOI: /j.bbmt
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
TRM and relapse. The actuarial 3-year cumulative incidences of TRM (A) and MM relapse or progression (B) were 29% and 50%, respectively.
Biology of Blood and Marrow Transplantation  , 54-60DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
OS and PFS. The actuarial 3-year OS (A) and PFS (B) rates were 29% and 15%, respectively.
Biology of Blood and Marrow Transplantation  , 54-60DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Grade III and IV acute GVHD and chronic GVHD. The actuarial cumulative incidences of grade III and IV acute GHVD at day 180 (A) and chronic GVHD at 1 year (B) were 23% and 68%, respectively.
Biology of Blood and Marrow Transplantation  , 54-60DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions